FDA approves botulinum toxin A to reduce appearance of wrinkles

07/26/2011 | SkinAndAllergyNews.com

The FDA approved Merz Aesthetics' Xeomin, or incobotulinumtoxinA, for temporarily reducing skin lines and wrinkles. The product is expected to be available in the U.S. next year. Dermatologist and trial investigator Joel Cohen said incobotulinumtoxinA is "more similar than it is different to other products that are on the market, particularly Botox."

View Full Article in:

SkinAndAllergyNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC